Clinical Trial Update: Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating the safety and efficacy of FT218 for idiopathic hypersomnia, sponsored by Avadel under the REVITALYZ program.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Hypersomnia

Drugs mentioned

• FT218 (sodium oxybate extended-release)

Snippet

Sponsor: Avadel | Conditions: Idiopathic Hypersomnia | Phase 3 | Status: ACTIVE_NOT_RECRUITING